Publicaciones en colaboración con investigadores/as de Hospital de Cruces (5)

2022

  1. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

    Trials, Vol. 23, Núm. 1

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2017

  1. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

  2. Prognostic models for locally advanced cervical cancer: External validation of the published models

    Journal of Gynecologic Oncology, Vol. 28, Núm. 5

2014

  1. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: A propensity score analysis

    Clinical Infectious Diseases, Vol. 58, Núm. 10, pp. 1413-1421